Synapse protecting protein could be a target for Alzheimer’s therapies
Researchers suggest the SRPX2 protein, which inhibits complement system-dependent synapse removal could be a target for novel Alzheimer’s and schizophrenia therapies.
List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
Researchers suggest the SRPX2 protein, which inhibits complement system-dependent synapse removal could be a target for novel Alzheimer’s and schizophrenia therapies.
Researchers reveal a combination of PD1 immunotherapy and BMI1 protein inhibition eliminated cancer stem cells and prevented cancer recurrence in a mouse model.
Scientists demonstrate that vitronectin is responsible of the formation of deposits in dry age-related macular degeneration and suggest inhibitors could slow disease progression.
The novel aryl hydrocarbon receptor (AHR) inhibiting drug slowed zika virus replication and prevented mouse foetuses malforming in infected mothers.
Which immune cells contribute towards immune-induced neurodegeneration and how could this knowledge enable conditions such Alzheimer’s and multiple sclerosis to be treated?
A study of the SARS-CoV-2 nonstructural protein 1 (Nsp1) showed it can supress translation and inhibit anti-viral defence mechanisms, making it a potential target for drugs.
Researchers reveal drugs inhibiting Neuropilin-1 (NRP1), a protein expressed on T cells, could improve the efficacy of immunotherapies.
The novel nanoparticle delivered Mp6 peptide was able to inhibit thrombosis and reduce inflammation without increasing the risk of bleeding in mice after heart attacks.
The researchers suggest the regions they identified in their study could be targeted to improve dysfunctional behaviours associated with autism spectrum disorders, even in adults.
The newly identified hallmarks of critical COVID-19 indicate a combination of interferon supplementation and anti-inflammatory therapies could be effective in treating patients with severe COVID-19 symptoms.
Researchers reveal IgHV3-53 is the most common immunoglobulin mutation used to target the receptor binding domain on the SARS-CoV-2 spike protein.
Researchers reveal the Vav3 protein is responsible for the formation of bacterial docking stations in the airway cells which promote the recurrent lung infections seen in Cystic Fibrosis patients.
Scientists demonstrated that NELL2, a factor release by the testis, is essential for sperm to mature into motile cells able to fertilise an egg.
Scientists demonstrated that remdesivir can inhibit SARS-CoV-2 replication in human lung cells and improve lung function in mice with COVID-19.
The proteomic map based on data from 103 patients reveals novel prognostic biomarkers and potential drug targets for lung adenocarcinoma.